Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

TROPHY-U-01: Sacituzumab govitecan in patients with mUC after failure of platinum-based regimens or immunotherapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 07.10.19
Views: 602

Dr Scott Tagawa - Weill Cornell Medicine, New York City, USA

Dr Scott Tagawa speaks to ecancer at ESMO 2019 in Barcelona about the phase II TROPHY-U-01 study evaluating the use of sacituzumab govitecan in patients with metastatic urothelial cancer (mUC) after failure of platinum-based regimens or immunotherapy.

He explains that the main cohort contained 100 evaluable patients with mUC and progression of disease despite both platinum-based chemotherapy and checkpoint inhibitors.

Dr Tagawa reports that the response rate overall was 29% which was a marked improvement over single agent chemotherapy.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation